PDIA4 PROTEIN AS A TARGET FOR DIAGNOSIS, MONITORING AND TREATMENT OF DIABETES

專利類型

發明

專利國別 (專利申請國家)

美國

專利申請案號

15/302,938

專利證號

US 10,987,369 B2

專利獲證名稱

PDIA4 PROTEIN AS A TARGET FOR DIAGNOSIS, MONITORING AND TREATMENT OF DIABETES

專利所屬機關 (申請機關)

中央研究院

獲證日期

2021/04/27

技術說明

糖尿病是一種代謝疾病，人類目前仍無法逆轉或治癒糖尿病。本發明係一種用於逆轉第二型糖尿病之小分子化合物，該類化合物可以抑制PX活性。 本項發明技術是利用合成Pdia4 (PX)抑制劑來作為新式糖尿病小分子藥物，達到治療和逆轉糖尿病的效果。這些抑制劑的機制是增加胰島細胞功能及活存率。目前，本項發明台灣專利已取得，PCT專利正在申請中。由於本發明是新的抗糖尿病標靶與抑制劑，為市場首見(first-in-class)糖尿病小分子藥物。 Over 400 million people live with diabetes, which causes about 5 million deaths annually. The anti-diabetic drug market is valued 50 billion US dollars per year. These drugs include insulin sensitizers, insulin secretagogues, GLP1/DPP4 inhibitors, insulin and others. Unfortunately, type 2 diabetes (T2D) is now still an incurable disease. This invention relates to small-molecule drugs for treating T2D. These drugs are Pdia4(PX)-based inhibitors, which can reduce PX activity . As a result, they can treat and reverse T2D via a novel mode of action involving β-cell function and survival.

備註

連絡單位 (專責單位/部門名稱)

智財技轉處

連絡電話

02-2787-2508

網址